Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.200
-0.015 (-6.76%)
At close: Mar 9, 2026, 4:00 PM EDT
0.210
+0.010 (5.00%)
After-hours: Mar 9, 2026, 7:53 PM EDT
Virax Biolabs Group Ratios and Metrics
Market cap in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Market Capitalization | 1 | 5 | 2 | 11 | - | - | |
| Market Cap Growth | -81.21% | 192.29% | -84.34% | - | - | - | |
| Enterprise Value | -1 | -2 | -4 | 6 | - | - | |
| Last Close Price | 0.20 | 1.14 | 0.72 | 6.95 | - | - | |
| PS Ratio | 497.22 | 781.84 | 10.83 | 1262.87 | - | - | |
| PB Ratio | 0.25 | 0.91 | 0.33 | 1.21 | - | - | |
| P/TBV Ratio | 0.28 | 0.88 | 0.32 | 1.21 | - | - | |
| EV/Sales Ratio | - | - | - | 701.38 | - | - | |
| Debt / Equity Ratio | 0.11 | 0.13 | 0.04 | 0.02 | - | -0.21 | |
| Net Debt / Equity Ratio | -0.57 | -0.66 | -0.67 | -1.04 | 0.02 | -0.19 | |
| Net Debt / EBITDA Ratio | 0.52 | 0.61 | 0.57 | - | - | - | |
| Net Debt / FCF Ratio | 0.49 | 0.70 | 0.48 | 2.21 | 0.03 | -0.27 | |
| Asset Turnover | 0 | 0.00 | 0.02 | 0.00 | - | 3.98 | |
| Inventory Turnover | 0.27 | 0.32 | 1.01 | 0.44 | - | - | |
| Quick Ratio | 9.89 | 6.47 | 23.01 | 10.35 | 0.02 | 0.02 | |
| Current Ratio | 11.35 | 7.27 | 25.94 | 10.61 | 0.04 | 0.05 | |
| Return on Equity (ROE) | -83.82% | -114.47% | -95.98% | -141.63% | - | - | |
| Return on Assets (ROA) | -48.40% | -64.68% | -49.90% | -72.67% | -2453.52% | -1294.67% | |
| Return on Capital Employed (ROCE) | -109.70% | -107.10% | -114.90% | -64.40% | 144.90% | 77.50% | |
| Earnings Yield | -380.12% | -122.45% | -397.61% | -50.48% | - | - | |
| FCF Yield | -397.57% | -104.40% | -425.13% | -38.66% | - | - | |
| Buyback Yield / Dilution | -70.75% | -85.92% | -88.75% | -11.15% | -297.67% | -130.43% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.